Click for best price
Multivalent Vaccines Market Size, Share 2022
This report contains market size and forecasts of Multivalent Vaccines in global, including the following market information:
Global Multivalent Vaccines Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Multivalent Vaccines Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Multivalent Vaccines companies in 2021 (%)
The global Multivalent Vaccines market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Conjugate Vaccines Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Multivalent Vaccines include GlaxoSmithKline, plc (U.K.), Pfizer, Inc (US), Merck & Co., Inc (US), Sanofi Pasteur SA (France), Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc (US), Johnson & Johnson (US) and MedImmune, LLC (US), etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Multivalent Vaccines manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Multivalent Vaccines Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Multivalent Vaccines Market Segment Percentages, by Type, 2021 (%)
Conjugate Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Recombinant Vaccines
Global Multivalent Vaccines Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Multivalent Vaccines Market Segment Percentages, by Application, 2021 (%)
Pediatrics
Adults
Global Multivalent Vaccines Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Multivalent Vaccines Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Multivalent Vaccines revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Multivalent Vaccines revenues share in global market, 2021 (%)
Key companies Multivalent Vaccines sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Multivalent Vaccines sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
GlaxoSmithKline, plc (U.K.)
Pfizer, Inc (US)
Merck & Co., Inc (US)
Sanofi Pasteur SA (France)
Astellas Pharma Inc. (Japan)
CSL Limited (Australia)
Emergent BioSolutions, Inc (US)
Johnson & Johnson (US)
MedImmune, LLC (US)
Serum Institute of India Pvt. Ltd. (India)
Bavarian Nordic (Denmark)
Mitsubishi Tanabe Pharma Corporation (Japan)
Daiichi Sankyo (Japan)
Protein Sciences Corporation (US)
Panacea Biotec (India)
| Report Attributes |
Report Details |
| Report Title |
Multivalent Vaccines Market, Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
116 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Multivalent Vaccines Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Multivalent Vaccines Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Multivalent Vaccines Overall Market Size
2.1 Global Multivalent Vaccines Market Size: 2021 VS 2028
2.2 Global Multivalent Vaccines Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Multivalent Vaccines Sales: 2017-2028
3 Company Landscape
3.1 Top Multivalent Vaccines Players in Global Market
3.2 Top Global Multivalent Vaccines Companies Ranked by Revenue
3.3 Global Multivalent Vaccines Revenue by Companies
3.4 Global Multivalent Vaccines Sales by Companies
3.5 Global Multivalent Vaccines Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Multivalent Vaccines Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Multivalent Vaccines Product Type
3.8 Tier 1, Tier 2 and Tier 3 Multivalent Vaccines Players in Global Market
3.8.1 List of Global Tier 1 Multivalent Vaccines Companies
3.8.2 List of Global Tier 2 and Tier 3 Multivalent Vaccines Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Multivalent Vaccines Market Size Markets, 2021 & 2028
4.1.2 Conjugate Vaccines
4.1.3 Inactivated and Subunit Vaccines
4.1.4 Live Attenuated Vaccines
4.1.5 Toxoid Vaccines
4.1.6 Recombinant Vaccines
4.2 By Type - Global Multivalent Vaccines Revenue & Forecasts
4.2.1 By Type - Global Multivalent Vaccines Revenue, 2017-2022
4.2.2 By Type - Global Multivalent Vaccines Revenue, 2023-2028
4.2.3 By Type - Global Multivalent Vaccines Revenue Market Share, 2017-2028
4.3 By Type - Global Multivalent Vaccines Sales & Forecasts
4.3.1 By Type - Global Multivalent Vaccines Sales, 2017-2022
4.3.2 By Type - Global Multivalent Vaccines Sales, 2023-2028
4.3.3 By Type - Global Multivalent Vaccines Sales Market Share, 2017-2028
4.4 By Type - Global Multivalent Vaccines Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application - Global Multivalent Vaccines Market Size, 2021 & 2028
5.1.2 Pediatrics
5.1.3 Adults
5.2 By Application - Global Multivalent Vaccines Revenue & Forecasts
5.2.1 By Application - Global Multivalent Vaccines Revenue, 2017-2022
5.2.2 By Application - Global Multivalent Vaccines Revenue, 2023-2028
5.2.3 By Application - Global Multivalent Vaccines Revenue Market Share, 2017-2028
5.3 By Application - Global Multivalent Vaccines Sales & Forecasts
5.3.1 By Application - Global Multivalent Vaccines Sales, 2017-2022
5.3.2 By Application - Global Multivalent Vaccines Sales, 2023-2028
5.3.3 By Application - Global Multivalent Vaccines Sales Market Share, 2017-2028
5.4 By Application - Global Multivalent Vaccines Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region - Global Multivalent Vaccines Market Size, 2021 & 2028
6.2 By Region - Global Multivalent Vaccines Revenue & Forecasts
6.2.1 By Region - Global Multivalent Vaccines Revenue, 2017-2022
6.2.2 By Region - Global Multivalent Vaccines Revenue, 2023-2028
6.2.3 By Region - Global Multivalent Vaccines Revenue Market Share, 2017-2028
6.3 By Region - Global Multivalent Vaccines Sales & Forecasts
6.3.1 By Region - Global Multivalent Vaccines Sales, 2017-2022
6.3.2 By Region - Global Multivalent Vaccines Sales, 2023-2028
6.3.3 By Region - Global Multivalent Vaccines Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country - North America Multivalent Vaccines Revenue, 2017-2028
6.4.2 By Country - North America Multivalent Vaccines Sales, 2017-2028
6.4.3 US Multivalent Vaccines Market Size, 2017-2028
6.4.4 Canada Multivalent Vaccines Market Size, 2017-2028
6.4.5 Mexico Multivalent Vaccines Market Size, 2017-2028
6.5 Europe
6.5.1 By Country - Europe Multivalent Vaccines Revenue, 2017-2028
6.5.2 By Country - Europe Multivalent Vaccines Sales, 2017-2028
6.5.3 Germany Multivalent Vaccines Market Size, 2017-2028
6.5.4 France Multivalent Vaccines Market Size, 2017-2028
6.5.5 U.K. Multivalent Vaccines Market Size, 2017-2028
6.5.6 Italy Multivalent Vaccines Market Size, 2017-2028
6.5.7 Russia Multivalent Vaccines Market Size, 2017-2028
6.5.8 Nordic Countries Multivalent Vaccines Market Size, 2017-2028
6.5.9 Benelux Multivalent Vaccines Market Size, 2017-2028
6.6 Asia
6.6.1 By Region - Asia Multivalent Vaccines Revenue, 2017-2028
6.6.2 By Region - Asia Multivalent Vaccines Sales, 2017-2028
6.6.3 China Multivalent Vaccines Market Size, 2017-2028
6.6.4 Japan Multivalent Vaccines Market Size, 2017-2028
6.6.5 South Korea Multivalent Vaccines Market Size, 2017-2028
6.6.6 Southeast Asia Multivalent Vaccines Market Size, 2017-2028
6.6.7 India Multivalent Vaccines Market Size, 2017-2028
6.7 South America
6.7.1 By Country - South America Multivalent Vaccines Revenue, 2017-2028
6.7.2 By Country - South America Multivalent Vaccines Sales, 2017-2028
6.7.3 Brazil Multivalent Vaccines Market Size, 2017-2028
6.7.4 Argentina Multivalent Vaccines Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Multivalent Vaccines Revenue, 2017-2028
6.8.2 By Country - Middle East & Africa Multivalent Vaccines Sales, 2017-2028
6.8.3 Turkey Multivalent Vaccines Market Size, 2017-2028
6.8.4 Israel Multivalent Vaccines Market Size, 2017-2028
6.8.5 Saudi Arabia Multivalent Vaccines Market Size, 2017-2028
6.8.6 UAE Multivalent Vaccines Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 GlaxoSmithKline, plc (U.K.)
7.1.1 GlaxoSmithKline, plc (U.K.) Corporate Summary
7.1.2 GlaxoSmithKline, plc (U.K.) Business Overview
7.1.3 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Major Product Offerings
7.1.4 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales and Revenue in Global (2017-2022)
7.1.5 GlaxoSmithKline, plc (U.K.) Key News
7.2 Pfizer, Inc (US)
7.2.1 Pfizer, Inc (US) Corporate Summary
7.2.2 Pfizer, Inc (US) Business Overview
7.2.3 Pfizer, Inc (US) Multivalent Vaccines Major Product Offerings
7.2.4 Pfizer, Inc (US) Multivalent Vaccines Sales and Revenue in Global (2017-2022)
7.2.5 Pfizer, Inc (US) Key News
7.3 Merck & Co., Inc (US)
7.3.1 Merck & Co., Inc (US) Corporate Summary
7.3.2 Merck & Co., Inc (US) Business Overview
7.3.3 Merck & Co., Inc (US) Multivalent Vaccines Major Product Offerings
7.3.4 Merck & Co., Inc (US) Multivalent Vaccines Sales and Revenue in Global (2017-2022)
7.3.5 Merck & Co., Inc (US) Key News
7.4 Sanofi Pasteur SA (France)
7.4.1 Sanofi Pasteur SA (France) Corporate Summary
7.4.2 Sanofi Pasteur SA (France) Business Overview
7.4.3 Sanofi Pasteur SA (France) Multivalent Vaccines Major Product Offerings
7.4.4 Sanofi Pasteur SA (France) Multivalent Vaccines Sales and Revenue in Global (2017-2022)
7.4.5 Sanofi Pasteur SA (France) Key News
7.5 Astellas Pharma Inc. (Japan)
7.5.1 Astellas Pharma Inc. (Japan) Corporate Summary
7.5.2 Astellas Pharma Inc. (Japan) Business Overview
7.5.3 Astellas Pharma Inc. (Japan) Multivalent Vaccines Major Product Offerings
7.5.4 Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales and Revenue in Global (2017-2022)
7.5.5 Astellas Pharma Inc. (Japan) Key News
7.6 CSL Limited (Australia)
7.6.1 CSL Limited (Australia) Corporate Summary
7.6.2 CSL Limited (Australia) Business Overview
7.6.3 CSL Limited (Australia) Multivalent Vaccines Major Product Offerings
7.6.4 CSL Limited (Australia) Multivalent Vaccines Sales and Revenue in Global (2017-2022)
7.6.5 CSL Limited (Australia) Key News
7.7 Emergent BioSolutions, Inc (US)
7.7.1 Emergent BioSolutions, Inc (US) Corporate Summary
7.7.2 Emergent BioSolutions, Inc (US) Business Overview
7.7.3 Emergent BioSolutions, Inc (US) Multivalent Vaccines Major Product Offerings
7.7.4 Emergent BioSolutions, Inc (US) Multivalent Vaccines Sales and Revenue in Global (2017-2022)
7.7.5 Emergent BioSolutions, Inc (US) Key News
7.8 Johnson & Johnson (US)
7.8.1 Johnson & Johnson (US) Corporate Summary
7.8.2 Johnson & Johnson (US) Business Overview
7.8.3 Johnson & Johnson (US) Multivalent Vaccines Major Product Offerings
7.8.4 Johnson & Johnson (US) Multivalent Vaccines Sales and Revenue in Global (2017-2022)
7.8.5 Johnson & Johnson (US) Key News
7.9 MedImmune, LLC (US)
7.9.1 MedImmune, LLC (US) Corporate Summary
7.9.2 MedImmune, LLC (US) Business Overview
7.9.3 MedImmune, LLC (US) Multivalent Vaccines Major Product Offerings
7.9.4 MedImmune, LLC (US) Multivalent Vaccines Sales and Revenue in Global (2017-2022)
7.9.5 MedImmune, LLC (US) Key News
7.10 Serum Institute of India Pvt. Ltd. (India)
7.10.1 Serum Institute of India Pvt. Ltd. (India) Corporate Summary
7.10.2 Serum Institute of India Pvt. Ltd. (India) Business Overview
7.10.3 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Major Product Offerings
7.10.4 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales and Revenue in Global (2017-2022)
7.10.5 Serum Institute of India Pvt. Ltd. (India) Key News
7.11 Bavarian Nordic (Denmark)
7.11.1 Bavarian Nordic (Denmark) Corporate Summary
7.11.2 Bavarian Nordic (Denmark) Multivalent Vaccines Business Overview
7.11.3 Bavarian Nordic (Denmark) Multivalent Vaccines Major Product Offerings
7.11.4 Bavarian Nordic (Denmark) Multivalent Vaccines Sales and Revenue in Global (2017-2022)
7.11.5 Bavarian Nordic (Denmark) Key News
7.12 Mitsubishi Tanabe Pharma Corporation (Japan)
7.12.1 Mitsubishi Tanabe Pharma Corporation (Japan) Corporate Summary
7.12.2 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Business Overview
7.12.3 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Major Product Offerings
7.12.4 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales and Revenue in Global (2017-2022)
7.12.5 Mitsubishi Tanabe Pharma Corporation (Japan) Key News
7.13 Daiichi Sankyo (Japan)
7.13.1 Daiichi Sankyo (Japan) Corporate Summary
7.13.2 Daiichi Sankyo (Japan) Multivalent Vaccines Business Overview
7.13.3 Daiichi Sankyo (Japan) Multivalent Vaccines Major Product Offerings
7.13.4 Daiichi Sankyo (Japan) Multivalent Vaccines Sales and Revenue in Global (2017-2022)
7.13.5 Daiichi Sankyo (Japan) Key News
7.14 Protein Sciences Corporation (US)
7.14.1 Protein Sciences Corporation (US) Corporate Summary
7.14.2 Protein Sciences Corporation (US) Business Overview
7.14.3 Protein Sciences Corporation (US) Multivalent Vaccines Major Product Offerings
7.14.4 Protein Sciences Corporation (US) Multivalent Vaccines Sales and Revenue in Global (2017-2022)
7.14.5 Protein Sciences Corporation (US) Key News
7.15 Panacea Biotec (India)
7.15.1 Panacea Biotec (India) Corporate Summary
7.15.2 Panacea Biotec (India) Business Overview
7.15.3 Panacea Biotec (India) Multivalent Vaccines Major Product Offerings
7.15.4 Panacea Biotec (India) Multivalent Vaccines Sales and Revenue in Global (2017-2022)
7.15.5 Panacea Biotec (India) Key News
8 Global Multivalent Vaccines Production Capacity, Analysis
8.1 Global Multivalent Vaccines Production Capacity, 2017-2028
8.2 Multivalent Vaccines Production Capacity of Key Manufacturers in Global Market
8.3 Global Multivalent Vaccines Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Multivalent Vaccines Supply Chain Analysis
10.1 Multivalent Vaccines Industry Value Chain
10.2 Multivalent Vaccines Upstream Market
10.3 Multivalent Vaccines Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Multivalent Vaccines Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Multivalent Vaccines in Global Market
Table 2. Top Multivalent Vaccines Players in Global Market, Ranking by Revenue (2021)
Table 3. Global Multivalent Vaccines Revenue by Companies, (US$, Mn), 2017-2022
Table 4. Global Multivalent Vaccines Revenue Share by Companies, 2017-2022
Table 5. Global Multivalent Vaccines Sales by Companies, (K Pcs), 2017-2022
Table 6. Global Multivalent Vaccines Sales Share by Companies, 2017-2022
Table 7. Key Manufacturers Multivalent Vaccines Price (2017-2022) & (USD/Pcs)
Table 8. Global Manufacturers Multivalent Vaccines Product Type
Table 9. List of Global Tier 1 Multivalent Vaccines Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Multivalent Vaccines Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Multivalent Vaccines Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Global Multivalent Vaccines Revenue (US$, Mn), 2017-2022
Table 13. By Type - Global Multivalent Vaccines Revenue (US$, Mn), 2023-2028
Table 14. By Type - Global Multivalent Vaccines Sales (K Pcs), 2017-2022
Table 15. By Type - Global Multivalent Vaccines Sales (K Pcs), 2023-2028
Table 16. By Application ? Global Multivalent Vaccines Revenue, (US$, Mn), 2021 & 2028
Table 17. By Application - Global Multivalent Vaccines Revenue (US$, Mn), 2017-2022
Table 18. By Application - Global Multivalent Vaccines Revenue (US$, Mn), 2023-2028
Table 19. By Application - Global Multivalent Vaccines Sales (K Pcs), 2017-2022
Table 20. By Application - Global Multivalent Vaccines Sales (K Pcs), 2023-2028
Table 21. By Region ? Global Multivalent Vaccines Revenue, (US$, Mn), 2021 VS 2028
Table 22. By Region - Global Multivalent Vaccines Revenue (US$, Mn), 2017-2022
Table 23. By Region - Global Multivalent Vaccines Revenue (US$, Mn), 2023-2028
Table 24. By Region - Global Multivalent Vaccines Sales (K Pcs), 2017-2022
Table 25. By Region - Global Multivalent Vaccines Sales (K Pcs), 2023-2028
Table 26. By Country - North America Multivalent Vaccines Revenue, (US$, Mn), 2017-2022
Table 27. By Country - North America Multivalent Vaccines Revenue, (US$, Mn), 2023-2028
Table 28. By Country - North America Multivalent Vaccines Sales, (K Pcs), 2017-2022
Table 29. By Country - North America Multivalent Vaccines Sales, (K Pcs), 2023-2028
Table 30. By Country - Europe Multivalent Vaccines Revenue, (US$, Mn), 2017-2022
Table 31. By Country - Europe Multivalent Vaccines Revenue, (US$, Mn), 2023-2028
Table 32. By Country - Europe Multivalent Vaccines Sales, (K Pcs), 2017-2022
Table 33. By Country - Europe Multivalent Vaccines Sales, (K Pcs), 2023-2028
Table 34. By Region - Asia Multivalent Vaccines Revenue, (US$, Mn), 2017-2022
Table 35. By Region - Asia Multivalent Vaccines Revenue, (US$, Mn), 2023-2028
Table 36. By Region - Asia Multivalent Vaccines Sales, (K Pcs), 2017-2022
Table 37. By Region - Asia Multivalent Vaccines Sales, (K Pcs), 2023-2028
Table 38. By Country - South America Multivalent Vaccines Revenue, (US$, Mn), 2017-2022
Table 39. By Country - South America Multivalent Vaccines Revenue, (US$, Mn), 2023-2028
Table 40. By Country - South America Multivalent Vaccines Sales, (K Pcs), 2017-2022
Table 41. By Country - South America Multivalent Vaccines Sales, (K Pcs), 2023-2028
Table 42. By Country - Middle East & Africa Multivalent Vaccines Revenue, (US$, Mn), 2017-2022
Table 43. By Country - Middle East & Africa Multivalent Vaccines Revenue, (US$, Mn), 2023-2028
Table 44. By Country - Middle East & Africa Multivalent Vaccines Sales, (K Pcs), 2017-2022
Table 45. By Country - Middle East & Africa Multivalent Vaccines Sales, (K Pcs), 2023-2028
Table 46. GlaxoSmithKline, plc (U.K.) Corporate Summary
Table 47. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Product Offerings
Table 48. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 49. Pfizer, Inc (US) Corporate Summary
Table 50. Pfizer, Inc (US) Multivalent Vaccines Product Offerings
Table 51. Pfizer, Inc (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 52. Merck & Co., Inc (US) Corporate Summary
Table 53. Merck & Co., Inc (US) Multivalent Vaccines Product Offerings
Table 54. Merck & Co., Inc (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 55. Sanofi Pasteur SA (France) Corporate Summary
Table 56. Sanofi Pasteur SA (France) Multivalent Vaccines Product Offerings
Table 57. Sanofi Pasteur SA (France) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 58. Astellas Pharma Inc. (Japan) Corporate Summary
Table 59. Astellas Pharma Inc. (Japan) Multivalent Vaccines Product Offerings
Table 60. Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 61. CSL Limited (Australia) Corporate Summary
Table 62. CSL Limited (Australia) Multivalent Vaccines Product Offerings
Table 63. CSL Limited (Australia) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 64. Emergent BioSolutions, Inc (US) Corporate Summary
Table 65. Emergent BioSolutions, Inc (US) Multivalent Vaccines Product Offerings
Table 66. Emergent BioSolutions, Inc (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 67. Johnson & Johnson (US) Corporate Summary
Table 68. Johnson & Johnson (US) Multivalent Vaccines Product Offerings
Table 69. Johnson & Johnson (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 70. MedImmune, LLC (US) Corporate Summary
Table 71. MedImmune, LLC (US) Multivalent Vaccines Product Offerings
Table 72. MedImmune, LLC (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 73. Serum Institute of India Pvt. Ltd. (India) Corporate Summary
Table 74. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Product Offerings
Table 75. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 76. Bavarian Nordic (Denmark) Corporate Summary
Table 77. Bavarian Nordic (Denmark) Multivalent Vaccines Product Offerings
Table 78. Bavarian Nordic (Denmark) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 79. Mitsubishi Tanabe Pharma Corporation (Japan) Corporate Summary
Table 80. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product Offerings
Table 81. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 82. Daiichi Sankyo (Japan) Corporate Summary
Table 83. Daiichi Sankyo (Japan) Multivalent Vaccines Product Offerings
Table 84. Daiichi Sankyo (Japan) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 85. Protein Sciences Corporation (US) Corporate Summary
Table 86. Protein Sciences Corporation (US) Multivalent Vaccines Product Offerings
Table 87. Protein Sciences Corporation (US) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 88. Panacea Biotec (India) Corporate Summary
Table 89. Panacea Biotec (India) Multivalent Vaccines Product Offerings
Table 90. Panacea Biotec (India) Multivalent Vaccines Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2017-2022)
Table 91. Multivalent Vaccines Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2020-2022 (K Pcs)
Table 92. Global Multivalent Vaccines Capacity Market Share of Key Manufacturers, 2020-2022
Table 93. Global Multivalent Vaccines Production by Region, 2017-2022 (K Pcs)
Table 94. Global Multivalent Vaccines Production by Region, 2023-2028 (K Pcs)
Table 95. Multivalent Vaccines Market Opportunities & Trends in Global Market
Table 96. Multivalent Vaccines Market Drivers in Global Market
Table 97. Multivalent Vaccines Market Restraints in Global Market
Table 98. Multivalent Vaccines Raw Materials
Table 99. Multivalent Vaccines Raw Materials Suppliers in Global Market
Table 100. Typical Multivalent Vaccines Downstream
Table 101. Multivalent Vaccines Downstream Clients in Global Market
Table 102. Multivalent Vaccines Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Multivalent Vaccines Segment by Type
Figure 2. Multivalent Vaccines Segment by Application
Figure 3. Global Multivalent Vaccines Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Multivalent Vaccines Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Multivalent Vaccines Revenue, 2017-2028 (US$, Mn)
Figure 7. Multivalent Vaccines Sales in Global Market: 2017-2028 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Multivalent Vaccines Revenue in 2021
Figure 9. By Type - Global Multivalent Vaccines Sales Market Share, 2017-2028
Figure 10. By Type - Global Multivalent Vaccines Revenue Market Share, 2017-2028
Figure 11. By Type - Global Multivalent Vaccines Price (USD/Pcs), 2017-2028
Figure 12. By Application - Global Multivalent Vaccines Sales Market Share, 2017-2028
Figure 13. By Application - Global Multivalent Vaccines Revenue Market Share, 2017-2028
Figure 14. By Application - Global Multivalent Vaccines Price (USD/Pcs), 2017-2028
Figure 15. By Region - Global Multivalent Vaccines Sales Market Share, 2017-2028
Figure 16. By Region - Global Multivalent Vaccines Revenue Market Share, 2017-2028
Figure 17. By Country - North America Multivalent Vaccines Revenue Market Share, 2017-2028
Figure 18. By Country - North America Multivalent Vaccines Sales Market Share, 2017-2028
Figure 19. US Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 20. Canada Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 21. Mexico Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 22. By Country - Europe Multivalent Vaccines Revenue Market Share, 2017-2028
Figure 23. By Country - Europe Multivalent Vaccines Sales Market Share, 2017-2028
Figure 24. Germany Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 25. France Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 26. U.K. Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 27. Italy Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 28. Russia Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 29. Nordic Countries Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 30. Benelux Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 31. By Region - Asia Multivalent Vaccines Revenue Market Share, 2017-2028
Figure 32. By Region - Asia Multivalent Vaccines Sales Market Share, 2017-2028
Figure 33. China Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 34. Japan Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 35. South Korea Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 36. Southeast Asia Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 37. India Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 38. By Country - South America Multivalent Vaccines Revenue Market Share, 2017-2028
Figure 39. By Country - South America Multivalent Vaccines Sales Market Share, 2017-2028
Figure 40. Brazil Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 41. Argentina Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 42. By Country - Middle East & Africa Multivalent Vaccines Revenue Market Share, 2017-2028
Figure 43. By Country - Middle East & Africa Multivalent Vaccines Sales Market Share, 2017-2028
Figure 44. Turkey Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 45. Israel Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 46. Saudi Arabia Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 47. UAE Multivalent Vaccines Revenue, (US$, Mn), 2017-2028
Figure 48. Global Multivalent Vaccines Production Capacity (K Pcs), 2017-2028
Figure 49. The Percentage of Production Multivalent Vaccines by Region, 2021 VS 2028
Figure 50. Multivalent Vaccines Industry Value Chain
Figure 51. Marketing Channels
